On Friday, Natera's stock saw a significant increase following the announcement of a substantial increase in volume for its cancer-detecting blood test, Signatera, during the second quarter. The post highlights that Natera, listed on the IBD 50 Stock, has entered a profit-taking zone due to its remarkable performance in the quarter. This surge in stock price was triggered by the positive reception towards Signatera's performance, signifying a strong quarter for Natera in terms of market response.